Advokatfirman Lindahl advises NeuroVive Pharmaceutical AB (publ), listed on Nasdaq Stockholm, in connection with its directed share issue. The share issue has been directed to a limited group of Swedish and international institutional qualified investors through a private placement. In total, NeuroVive has raised approximately MSEK 65 through the issue before transaction costs.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases.
Lindahl's team consisted of Annika Andersson (Capital Markets and public M&A), Maria Arnoldsson, Gabriela Baier-Sandén and Olivia Flink (Capital Markets and public M&A), Jonas Löfgren (Life Science), Jonas Westerberg and Annie Kabala (Intellectual Property) and Anna Romell Stenmark and Angelica Olsson (Tax).
